We sit down with you and build your perfect lead list. Book a call with founders.
Sign Up
Login

Entelexo Analysis: $125K Raised

What is Entelexo?

Entelexo develops exosome-based therapeutics targeting autoimmune diseases, utilizing engineered exosomes for communication with specific cell types.
Founded
2020
Revenue
$5M
Company Stage
Seed
Investors
- Founders, Inc. - Y Combinator
YC Batch
W21

Product Features & Capabilities

  • engineered exosomes for autoimmune diseases, therapeutic exosome-based products, rapid prototyping of therapeutics, indication-specific exosome treatments, communication with multiple cell types

How much Entelexo raised

Seed - $125,000

March 24, 2021
Lead Investor: Y Combinator

Who are the founders of Entelexo

MR

Milad Riazifar

Co-Founder

TS

Todd Schurr

Co-Founder

CT

Cameron Taylor

Co-Founder and CTO

Find more companies like Entelexo

in YC W21 - Winter 2021

Financial Overview

$5MEstimated Revenue
$125KTotal Raised
Seed$125,000
March 24, 2021
Investors: Y Combinator
Want to research more data points on Entelexo?
Start with Extruct

Platform Links

LinkedInFollow on LinkedInWebsiteOfficial WebsitePitchBookView on PitchBookZoomInfoView on ZoomInfo
Extruct
© Copyright 2026, All Rights Reserved
Linkedin